Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:08:13.471Z.
Consensus retrieved: 2026-10-06T15:36:55.156Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:08:13.471Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 651b3973db42e019715e3a8a4e975a06fcddd3d3dc4e12dda44c0d1ac22a80ea
FORWARD PE RATIO
N/A
Quantum BioPharma Ltd.
Market Cap
$19.77M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Quantum BioPharma Ltd. (QNTM) | $19.77M | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.42M | N/A |
| NextCure, Inc. (NXTC)vs › | $20.53M | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.65M | N/A |
| P3 Health Partners Inc. (PIII)vs › | $18.41M | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.30M | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.39M | N/A |
| Lipocine Inc. (LPCN)vs › | $17.31M | N/A |
| Modular Medical, Inc. (MODD)vs › | $22.25M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in USD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
